Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Juvenile Idiopathic Arthritis in Children in Estonia.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01905319
Recruitment Status : Completed
First Posted : July 23, 2013
Last Update Posted : March 25, 2020
Sponsor:
Information provided by (Responsible Party):
Chris Pruunsild, University of Tartu

Brief Summary:

Aims of the study:

  • to study the incidence rate of juvenile idiopathic arthritis (JIA) and it's clinical subtypes in Estonia for the years 1998-2000;
  • to examine the course and short-term clinical outcome of JIA.

Method: a prospective population-based study carried on in 14 counties of Estonia


Condition or disease Intervention/treatment
Epidemiology Other: Blood collecting for storage of samples

Layout table for study information
Study Type : Observational
Actual Enrollment : 162 participants
Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Juvenile Idiopathic Arthritis in Children in Estonia - an Epidemiological and Clinical Investigation.
Study Start Date : January 1998
Actual Primary Completion Date : December 2000
Actual Study Completion Date : December 2002

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Subsequent new juvenile arthritis cases
During years 1998-2000, all new subsequent cases of juvenile idiopathic arthritis diagnosed in Estonia were included in the study group.
Other: Blood collecting for storage of samples



Primary Outcome Measures :
  1. Mean annual incidence rate of juvenile idiopathic arthritis in Estonia during years 1998-2000. [ Time Frame: 3 years ]

Biospecimen Retention:   Samples Without DNA
Sera and plasma.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
During years 1998-2000, 162 newly-diagnosed juvenile idiopathic arthritis cases from 14 counties of Estonia, were included to the study, among them 76 boys and 86 girls.
Criteria

Inclusion Criteria:

  • The International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis
  • children aged 0-15 years who had arthritis of an unknown cause for at least six weeks with an onset of the disease during the study period

Exclusion Criteria:

  • Children with infectious arthritis, postinfectious arthritis, traumatic arthritis and systemic connective tissue diseases
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Chris Pruunsild, MD, PhD, University of Tartu
ClinicalTrials.gov Identifier: NCT01905319    
Other Study ID Numbers: TARLA 0475;DARLA 0500
First Posted: July 23, 2013    Key Record Dates
Last Update Posted: March 25, 2020
Last Verified: March 2020
Keywords provided by Chris Pruunsild, University of Tartu:
juvenile idiopathic arthritis
incidence rate
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases